Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Assembly Biosciences (ASMB) Invested Capital (2016 - 2025)

Assembly Biosciences has reported Invested Capital over the past 11 years, most recently at $206.8 million for Q4 2025.

  • Quarterly results put Invested Capital at $206.8 million for Q4 2025, up 519.78% from a year ago — trailing twelve months through Dec 2025 was $206.8 million (up 519.78% YoY), and the annual figure for FY2025 was $206.8 million, up 519.78%.
  • Invested Capital for Q4 2025 was $206.8 million at Assembly Biosciences, up from $182.7 million in the prior quarter.
  • Over the last five years, Invested Capital for ASMB hit a ceiling of $247.2 million in Q1 2021 and a floor of $18.1 million in Q2 2025.
  • Median Invested Capital over the past 5 years was $76.5 million (2022), compared with a mean of $104.9 million.
  • Biggest five-year swings in Invested Capital: crashed 59.27% in 2023 and later surged 602.59% in 2025.
  • Assembly Biosciences' Invested Capital stood at $168.9 million in 2021, then tumbled by 51.07% to $82.7 million in 2022, then crashed by 50.28% to $41.1 million in 2023, then decreased by 18.83% to $33.4 million in 2024, then skyrocketed by 519.78% to $206.8 million in 2025.
  • The last three reported values for Invested Capital were $206.8 million (Q4 2025), $182.7 million (Q3 2025), and $18.1 million (Q2 2025) per Business Quant data.